UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 8.274

Sortiert nach

Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn

Pharmacological reviews, 2012-07, Vol.64 (3), p.540

2012

Link zum Volltext

Verfügbarkeit prüfen

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

The lancet respiratory medicine, 2021-11, Vol.9 (11), p.1266-1274

2021

Link zum Volltext

Verfügbarkeit prüfen

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor

Journal of the American Society of Nephrology, 2024-02, Vol.35 (2), p.149

2024

Link zum Volltext

Verfügbarkeit prüfen

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

Biochemical pharmacology, 2012-07, Vol.84 (1), p.68-75

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension

Biochemical pharmacology, 2019-08, Vol.166, p.242-252

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension

Trends in pharmacological sciences (Regular ed.), 2017-06, Vol.38 (6), p.512-523

2017

Link zum Volltext

Verfügbarkeit prüfen

Sexual dimorphism in prostacyclin-mimetic responses within rat mesenteric arteries: A novel role for K V 7.1 in shaping IP receptor-mediated relaxation

British journal of pharmacology, 2022-04, Vol.179 (7), p.1338-1352

2022

Link zum Volltext

Verfügbarkeit prüfen

Prostaglandin I2 Suppresses Proinflammatory Chemokine Expression, CD4 T Cell Activation, and STAT6-Independent Allergic Lung Inflammation

The Journal of immunology (1950), 2016-09, Vol.197 (5), p.1577-1586

2016

Link zum Volltext

Verfügbarkeit prüfen

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling

American journal of respiratory and critical care medicine, 2020-05, Vol.201 (10), p.1263-1276

2020

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug

The Journal of pharmacology and experimental therapeutics, 2017-12, Vol.363 (3), p.348

2017

Link zum Volltext

Verfügbarkeit prüfen

Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension

European journal of pharmacology, 2022-02, Vol.916, p.174484, Article 174484

2022

Link zum Volltext

Verfügbarkeit prüfen

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents

Chest, 2020-04, Vol.157 (4), p.955-965

2020

Link zum Volltext

Verfügbarkeit prüfen

Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2023-12, Vol.208 (11), p.1248

2023

Link zum Volltext

Verfügbarkeit prüfen

Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair

Cell research, 2017-08, Vol.27 (8), p.1002-1019

2017

Link zum Volltext

Verfügbarkeit prüfen

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β -Arrestin Recruitment and Desensitization Potential

The Journal of pharmacology and experimental therapeutics, 2017-07, Vol.362 (1), p.186

2017

Link zum Volltext

Verfügbarkeit prüfen

Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension

British journal of pharmacology, 2020-01, Vol.177 (1), p.161-174

2020

Link zum Volltext

Verfügbarkeit prüfen

P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation

British journal of clinical pharmacology, 2016-04, Vol.81 (4), p.621-633

2016

Link zum Volltext

Verfügbarkeit prüfen

KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration

European journal of pharmacology, 2015-05, Vol.754, p.179-189

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats

Pulmonary pharmacology & therapeutics, 2018-04, Vol.49, p.95-103

2018

Link zum Volltext

Verfügbarkeit prüfen

Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2010-11, Vol.182 (9), p.1161-1170

2010

Link zum Volltext

Verfügbarkeit prüfen

The Acute Effects of Prostacyclin on Right Ventricular Contractility and Pulmonary Artery Coupling

American journal of respiratory and critical care medicine, 2023-04, Vol.207 (8), p.1100-1102

2023

Link zum Volltext

Verfügbarkeit prüfen

Prostaglandin I 2 and T Regulatory Cell Function: Broader Impacts

DNA and cell biology, 2021-10, Vol.40 (10), p.1231

2021

Link zum Volltext

Verfügbarkeit prüfen

Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics

The Journal of heart and lung transplantation, 2013-05, Vol.32 (5), p.546-552

2013

Link zum Volltext

Verfügbarkeit prüfen

Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function

The Journal of pharmacology and experimental therapeutics, 2010-10, Vol.335 (1), p.249

2010

Link zum Volltext

Verfügbarkeit prüfen

Caveolin-1 regulates lipid droplet metabolism in endothelial cells via autocrine prostacyclin–stimulated, cAMP-mediated lipolysis

The Journal of biological chemistry, 2018-01, Vol.293 (3), p.973-983

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 8.274

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.696)
Mit Volltextzugriff
(5.894)

Publikationsform

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(5.940)
Life Sciences & Biomedicine
(5.818)
Animals
(5.394)
Humans
(3.820)
Epoprostenol - Pharmacology
(3.598)
Male
(3.477)
Biological And Medical Sciences
(3.379)
Female
(2.232)
Medical Sciences
(2.231)
Rats
(2.204)
Epoprostenol - Biosynthesis
(1.983)
Pharmacology & Pharmacy
(1.811)
Pharmacology. Drug Treatments
(1.467)
In Vitro Techniques
(1.417)
Epoprostenol - Metabolism
(1.402)
Prostacyclin
(1.273)
Platelet Aggregation - Drug Effects
(1.230)
Fundamental And Applied Biological Sciences. Psychology
(1.193)
Cardiovascular System & Cardiology
(1.151)
Cells, Cultured
(1.127)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension

Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension

Sexual dimorphism in prostacyclin-mimetic responses within rat mesenteric arteries: A novel role for K V 7.1 in shaping IP receptor-mediated relaxation

Prostaglandin I2 Suppresses Proinflammatory Chemokine Expression, CD4 T Cell Activation, and STAT6-Independent Allergic Lung Inflammation

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling

Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug

Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents

Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension

Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β -Arrestin Recruitment and Desensitization Potential

Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension

P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation

KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration

Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats

Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension

The Acute Effects of Prostacyclin on Right Ventricular Contractility and Pulmonary Artery Coupling

Prostaglandin I 2 and T Regulatory Cell Function: Broader Impacts

Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics

Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function

Caveolin-1 regulates lipid droplet metabolism in endothelial cells via autocrine prostacyclin–stimulated, cAMP-mediated lipolysis

Suchergebnisse filtern